The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000984392
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
6/07/2026
Date registered
Help: Date registered
11/08/2026
Date last updated
Help: Date last updated
11/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
11/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Evaluating a wearable Ambulatory Electrocardiogram (AECG) device for monitoring people with suspected abnormal heart rhythms
Scientific title
Validation of a three-lead wearable Ambulatory Electrocardiogram (AECG) device for patients with suspected cardiac arrythmias to compare quality of ECG data from existing AECG devices
Additional trial identifiers [1] 317703 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Cardiac Arrhythmias 342554 0
Condition category
Condition code
Cardiovascular 338699 338699 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants will wear the Lubdub ambulatory electrocardiogram (AECG) device concurrently with a clinically accepted comparator AECG device. The purpose of this study is to evaluate the signal quality and performance of the Lubdub device compared with the comparator device. Clinical diagnosis and patient management will be based exclusively on the comparator device and standard clinical care and will not be influenced by the investigational device.
The Lubdub AECG device is an investigational device measuring approximately 150 mm × 150 mm. It has a three-arm design that supports the placement of three electrodes. The device is applied to the skin over the participant's left pectoral region, positioned along the left midclavicular line between the second and third intercostal spaces, to record the heart's electrical activity.
Both devices will be applied by appropriately trained study personnel, including research staff and/or healthcare professionals experienced in the application and operation of AECG devices. All study personnel will receive training in the correct application, operation, and removal of the Lubdub AECG device before enrolling participants.
The Lubdub AECG device and the comparator AECG device will be fitted and activated simultaneously during a single study visit at the cardiology clinic. Following application, participants will be asked to continue their usual daily activities while wearing both devices throughout the prescribed monitoring period.
Participants will wear both the Lubdub AECG device and the comparator AECG device continuously for 24 to 48 hours, depending on the monitoring duration prescribed by their treating physician as part of routine clinical care. The duration of monitoring will be determined by the treating physician based on the participant's clinical presentation, including the frequency of symptoms or suspected arrhythmias.
The devices will be applied once at the commencement of monitoring and removed at the completion of the monitoring period. Participant adherence will be assessed using device wear-time records and by reviewing the ECG data collected from both devices. Participants will receive both verbal and written instructions regarding device care, including guidance on maintaining normal daily activities while ensuring the devices remain securely in place throughout the monitoring period
Intervention code [1] 334542 0
Diagnosis / Prognosis
Description of the comparator or control
The comparator is a clinically accepted AECG device routinely used for the detection and assessment of cardiac rhythm abnormalities, such as Holter and similar devices. The comparator AECG device is determined at the discretion of the treating clinician based on device availability and is used in all cases. Participants are already undergoing a prescribed monitoring period with the comparator AECG device. The comparator AECG device serves as the reference standard for clinical interpretation, diagnosis and comparison with the Lubdub AECG device.
The comparator AECG device will be applied by appropriately trained healthcare professionals or cardiac monitoring personnel experienced in AECG device application and operation. Personnel applying the device will follow the manufacturer's instructions and standard clinical procedures. Participants will continue their normal daily activities while wearing the device throughout the prescribed monitoring period.
Participants will wear the comparator AECG device continuously for the duration of the monitoring period, 24-48 hours. Device application occurs once at the commencement of monitoring, with device removal occurring at the completion of the monitoring period.
The comparator AECG will be applied in a clinical setting, such as a cardiology clinic. Following application, participants will wear the device in their usual home, work and community environments during the monitoring period.
Adherence will be monitored through device wear time records by reviewing the AECG data collected by the comparator device. Participants will receive standard instructions regarding device use, care and maintenance during the monitoring period as per the clinic's usual code of practice. Monitoring completion will be confirmed through successful retrieval of ECG data at the end of the monitoring period.

Control group
Active

Outcomes
Primary outcome [1] 345933 0
Validity of the Lubdub AECG device assessed by level of agreement with the comparator AECG device.
Timepoint [1] 345933 0
At completion of the monitoring period (24 to 48 hours after device application)
Primary outcome [2] 345934 0
Usability of Lubdub AECG device assessed by signal yield (defined as the ratio between usable ECG recording time and recording noise) between the Lubdub AECG device and the comparator AECG device
Timepoint [2] 345934 0
At completion of the monitoring period (24 to 48 hours after device application)
Secondary outcome [1] 463837 0
Participant-reported comfort of the Lubdub AECG device compared with the comparator AECG device.
Timepoint [1] 463837 0
At completion of the monitoring period (24 to 48 hours after device application)
Secondary outcome [2] 464457 0
Performance of battery
Timepoint [2] 464457 0
At completion of the monitoring period (24 to 48 hours after device application)
Secondary outcome [3] 464458 0
Activities during the onset of symptoms
Timepoint [3] 464458 0
At completion of the monitoring period (24 to 48 hours after device application)
Secondary outcome [4] 465832 0
Participant-reported impact of the Lubdub AECG device compared with the comparator AECG device during daily activities
Timepoint [4] 465832 0
End of the monitoring period (24 to 48 hours after device application).
Secondary outcome [5] 465833 0
Participant-reported usability of the Lubdub AECG device compared with the comparator AECG device.
Timepoint [5] 465833 0
End of the monitoring period (24 to 48 hours after device application).
Secondary outcome [6] 465834 0
Participant-reported cost acceptability of the Lubdub AECG device compared with the comparator AECG device.
Timepoint [6] 465834 0
End of the monitoring period (24 to 48 hours after device application).
Secondary outcome [7] 465835 0
Participant-reported device preference between the Lubdub AECG device and the comparator AECG device.
Timepoint [7] 465835 0
End of the monitoring period (24 to 48 hours after device application).

Eligibility
Key inclusion criteria
The participant has been referred for AECG monitoring as part of routine clinical care. Able and willing to provide written informed consent. Able and willing to wear both the Lubdub AECG device and a comparator AECG device concurrently for the required monitoring period, 24 to 48 hours. Able to comply with study procedures.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Participants undergoing surgery or invasive medical procedures during the monitoring period. Participants with known allergies, skin sensitivities, or dermatological conditions that may preclude safe use of the study devices. Participants with active implantable medical devices.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
A power analysis was conducted to determine the appropriate sample size for the study, assuming 90% power and an alpha level of 0.05. Consequently, all hypothesis tests will be evaluated at this significance threshold (p < 0.05).
Calculations were performed for all metrics - both amplitude and temporal markers - using data from Elango et al. (Elango et al., Applied Physics Reviews, 2023, DOI: 10.1063/5.0152554). Group comparisons were based on the percentage differences observed in these markers. Among all metrics, the largest required sample size was 46 participants per group, resulting in a total of 92 participants. When accounting for an anticipated attrition rate of 8%, the minimum required sample size increases to approximately 100 participants (99.36 rounded up)

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA

Funding & Sponsors
Funding source category [1] 322246 0
Commercial sector/Industry
Name [1] 322246 0
Lubdub Technologies Pty Ltd
Country [1] 322246 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Lubdub Technologies Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 325156 0
None
Name [1] 325156 0
Address [1] 325156 0
Country [1] 325156 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320769 0
Bellberry Human Research Ethics Committee Lower Risk
Ethics committee address [1] 320769 0
Ethics committee country [1] 320769 0
Australia
Date submitted for ethics approval [1] 320769 0
09/07/2025
Approval date [1] 320769 0
22/06/2026
Ethics approval number [1] 320769 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151554 0
Prof Girish Dwivedi
Address 151554 0
Lubdub Technologies, 24 Hasler Road, Stirling, 6017, WA
Country 151554 0
Australia
Phone 151554 0
+61 435091314
Fax 151554 0
Email 151554 0
Contact person for public queries
Name 151555 0
Dr. Nikhilesh Bappoo
Address 151555 0
Lubdub Technologies, 24 Hasler Road, Stirling, 6017, WA
Country 151555 0
Australia
Phone 151555 0
+61 406659568
Fax 151555 0
Email 151555 0
Contact person for scientific queries
Name 151556 0
Dr. Nikhilesh Bappoo
Address 151556 0
Lubdub Technologies, 24 Hasler Road, Stirling, 6017, WA
Country 151556 0
Australia
Phone 151556 0
+61 406659568
Fax 151556 0
Email 151556 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.